Disseminated intravascular coagulation

New England Journal of Medicine

Volumn 341, Issue 8, 1999, Pages 586-592

  Levi, Marcel ^a   Ten Cate, Hugo ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMNION FLUID EMBOLISM; CANCER; DISSEMINATED INTRAVASCULAR CLOTTING; HUMAN; INFECTION; INJURY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEPTICEMIA; SOLUTIO PLACENTAE; THROMBOTIC THROMBOCYTOPENIC PURPURA;

BLOOD COMPONENT TRANSFUSION; DISSEMINATED INTRAVASCULAR COAGULATION; HEMATOLOGIC AGENTS; HUMANS; PLASMA; PROGNOSIS;

EID: 0033584457     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199908193410807     Document Type: Review

References (52)

1. Marder VJ, Feinstein DI, Francis CW, Colman RW. Consumptive thrombohemorrhagic disorders. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and thrombosis: basic principles and clinical practice. 3rd ed. Philadelphia: J.B. Lippincott, 1994:1023-63.
2. Bone RC. Modulators of coagulation: a critical appraisal of their role in sepsis. Arch Intern Med 1992;152:1381-9.
3. Müller-Berghaus G, ten Cate H, Levi MM. Disseminated intravascular coagulation. In: Verstraete M, Fuster V, Topol EJ, eds. Cardiovascular thrombosis: thrombocardiology and thromboneurology. 2nd ed. Philadelphia: Lippincott-Raven, 1998:781-801.
4. Thijs LG, de Boer JP, de Groot MCM, Hack CE. Coagulation disorders in septic shock. Intensive Care Med 1993;19:Suppl 1:S8-S15.
5. Baglin T. Disseminated intravascular coagulation: diagnosis and treatment. BMJ 1996;312:683-7.
6. Gando S, Kameue T, Nanzaki S, Nakanishi Y. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost 1996;75:224-8.
7. Bone RC. Gram-positive organisms and sepsis. Arch Intern Med 1994; 154:26-34.
8. Hulka F, Mullins RJ, Frank EH. Blunt brain injury activates the coagulation process. Arch Surg 1996;131:923-8.
9. Boumen RMH, Hendriks T, van der Ven-Jongekrijg J, et al. Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma: relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann Surg 1993;6:769-76.
10. Gando S, Nakanishi Y, Tedo I. Cytokines and plasminogen activator inhibitor-1 in posttrauma disseminated intravascular coagulation: relationship to multiple organ dysfunction syndrome. Crit Care Med 1995;23: 1835-42.
11. Colman RW, Rubin RN. Disseminated intravascular coagulation due to malignancy. Semin Oncol 1990;17:172-86.
12. Sarris AH, Kempin S, Berman E, et al. High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia. Blood 1992;79:1305-10.
13. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of expression of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996;2:209-15.
14. Falanga A, Consonni R, Marchetti M, et al. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood 1998;92:143-51.
15. Weiner CP. The obstetric patient and disseminated intravascular coagulation. Clin Perinatol 1986;13:705-17.
16. Sibai BM, Spinnato JA, Watson DL, Hill GA, Anderson GD. Pregnancy outcome in 303 cases with severe preeclampsia. Obstet Gynecol 1984;64: 319-25.
17. Szlachetka DM. Kasabach-Merritt syndrome: a case review. Neonatal Netw 1998;17(1):7-15. [Erratum, Neonatal Netw 1998;17(3):21.]
18. Aboulafia DM, Aboulafia ED. Aortic aneurysm-induced disseminated intravascular coagulatbn. Ann Vasc Surg 1996;10:396-405.
19. Kazmers A, Jacobs L, Perkins A, Lindenauer SM, Bates E. Abdominal aortic aneurysm repair in Veterans Affairs medical centers. J Vasc Surg 1996;23:191-200.
20. Ruggenenti P, Lutz J, Remuzzi G. Pathogenesis and treatment of thrombotic microangiopathy. Kidney Int Suppl 1997;58:S97-S101.
21. Furlan M, Robles R, Galbusera M, et al. Von Willebrand actor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578-84.
22. Regoeczi E, Brain MC. Organ distribution of fibrin in disseminated intravascular coagulation. Br J Haematol 1969;17:73-81.
23. Creasey AA, Chang ACK, Feigen L, Wun TC, Taylor FB Jr, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993;91:2850-6.
24. Kessler CM, Tang Z, Jacobs HM, Szymanski LM. The suprapharmacological dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity. Blood 1997;89:4393-401.
25. Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation: compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992;101: 816-23.
26. van der Poll T, Büller HR, ten Cate H, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990;322:1622-7.
27. Levi M, van der Poll T, ten Cate H, van Deventer SJH. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxemia. Eur J Clin Invest 1997;27:3-9.
28. Levi M, ten Cate H, Bauer KA, et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994;93: 114-20.
29. Taylor FB Jr, Chang A, Ruf W, et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991;33:127-34.
30. Pixley RA, De La Cadena R, Page JD, et al. The contract system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia: in vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 1993;92:61-8.
31. Østerud B, Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb Haemost 1983;49:5-7.
32. Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast J. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 1996;88:881-6.
33. Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 1988;8:5588-92.
34. Taylor FB, Chang A, Ferrell G, et al. C4b-binding protein exacerbates the host response to Escherichia coli. Blood 1991;78:357-63.
35. Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activator after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989;320:1165-72.
36. Nossel HL. Relative proteolysis of the fibrinogen B beta chain by thrombin and plasmin as a determinant of thrombosis. Nature 1981;291: 165-7.
37. Bick RL. Disseminated intravascular coagulation: objective clinical and laboratory diagnosis, treatment, and assessment of therapeutic response. Semin Thromb Hemost 1996;22:69-88.
38. Bick RL, Baker WF. Diagnostic efficacy of the D-dimer assay in disseminated intravascular coagulation (DIC). Thromb Res 1992;65:785-90.
39. Wada H, Wakita Y, Nakase T, et al. Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation. Am J Hematol 1996;51:255-60.
40. Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood 1987;70:343-50.
41. Corrigan JJ Jr. Heparin therapy in bacterial septicemia. J Pediatr 1977; 91:695-700.
42. Feinstein DI. Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy. Blood 1982;60:284-7
43. Sakuragawa N, Hasegawa H, Maki M, Nakagawa M, Nakashima M. Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC) - a multicenter co-operative double-blind trial in comparison with heparin. Thromb Res 1993;72:475-500.
44. Feinstein DI. Treatment of disseminated intravascular coagulation. Semin Thromb Hemost 1988;14:351-62.
45. Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993;104: 882-8.
46. Baudo F, Caimi TM, de Cataldo F, et al. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med 1998;24:336-42.
47. Eisele B, Lamy M, Thijs LG, et al. Antithrombin III in patients with severe sepsis: a randomized placebo-controlled, double-blind multicenter trial plus meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 1998;24:663-72.
48. Levi M, de Jonge E, van der Poll T, ten Cate H. Disseminated intravascular coagulation: state of the art 1999. Thromb Haemost (in press).
49. Awisati G, ten Cate JW, Buller HR, Mandelli F. Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet 1989;2:122-4.
50. Bergum P, Cruikshank A, Maki S, Ruf W, Vlasuk G. The potent, factor X(a)-dependent inhibition by rNAPc2 of factor VIIa (FVIIa)/tissue factor involves the binding of its cofactor to a exosite on FVII, followed by occupation of the active site. Blood 1998;92:Suppl 1:669a. abstract.
51. Smith OP, White B, Vaughan D, et al. Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet 1997;350:1590-3.
52. Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987;79:918-25.